{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T07:42:40Z","timestamp":1781595760549,"version":"3.54.5"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"R1","license":[{"start":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T00:00:00Z","timestamp":1561161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100010663","name":"ERC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Finnish Academy Center of Excellence on Cardiovascular"},{"name":"Metabolic Diseases"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The prevalence of lipid disorders is alarmingly increasing in the Western world. They are the result of either primary causes, such as unhealthy lifestyle choices or inherited risk factors, or secondary causes like other diseases or medication. Atypical changes in the synthesis, processing and catabolism of lipoprotein particles may lead to severe hypercholesterolemia, hypertriglyceridemia or elevated Lp(a). Although cholesterol-lowering drugs are the most prescribed medications, not all patients achieve guideline recommended cholesterol levels with the current treatment options, emphasising the need for new therapies. Also, some lipid disorders do not have any treatment options but rely only on stringent dietary restriction. Patients with untreated lipid disorders carry a severe risk of cardiovascular disease, diabetes, non-alcoholic fatty liver disease and pancreatitis among others. To achieve better treatment outcome, novel selective gene expression and epigenetic targeting therapies are constantly being developed. Therapeutic innovations employing targeted RNA technology utilise small interfering RNAs, antisense oligonucleotides, long non-coding RNAs and microRNAs to regulate target protein production whereas viral gene therapy provides functional therapeutic genes and CRISPR\/Cas technology relies on gene editing and transcriptional regulation. In this review, we will discuss the latest advances in clinical trials for novel lipid-lowering therapies and potential new targets in pre-clinical phase.<\/jats:p>","DOI":"10.1093\/hmg\/ddz132","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T07:07:40Z","timestamp":1560150460000},"page":"R49-R54","source":"Crossref","is-referenced-by-count":21,"title":["Recent advances in novel therapies for lipid disorders"],"prefix":"10.1093","volume":"28","author":[{"given":"Annakaisa","family":"Tirronen","sequence":"first","affiliation":[{"name":"A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FIN-70211 Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Hokkanen","sequence":"additional","affiliation":[{"name":"A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FIN-70211 Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taina","family":"Vuorio","sequence":"additional","affiliation":[{"name":"A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FIN-70211 Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7593-2708","authenticated-orcid":false,"given":"Seppo","family":"Yl\u00e4-Herttuala","sequence":"additional","affiliation":[{"name":"A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FIN-70211 Kuopio, Finland"},{"name":"Heart Center and Gene Therapy Unit, Kuopio University Hospital P.O. Box 1777, FIN-70211 Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,22]]},"reference":[{"key":"2019101710385722100_ref1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cca.2018.09.010","article-title":"Dyslipidemias in clinical practice","volume":"487","author":"Castro Cabezas","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"2019101710385722100_ref2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"key":"2019101710385722100_ref3","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.cell.2008.09.008","article-title":"The Discovery of Statins","volume":"134","author":"Stossel","year":"2016","journal-title":"Cell"},{"key":"2019101710385722100_ref4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCGENETICS.116.001381","article-title":"Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States","volume":"9","author":"Goma","year":"2016","journal-title":"Circ. Cardiovasc. Genet."},{"key":"2019101710385722100_ref5","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-Acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"2019101710385722100_ref6","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2019101710385722100_ref7","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"key":"2019101710385722100_ref8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1517\/14740338.2013.793670","article-title":"Efficacy and safety of mipomersen sodium (Kynamro)","volume":"12","author":"Hovingh","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"2019101710385722100_ref9","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"2019101710385722100_ref10","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jacl.2017.04.071","article-title":"The APPROACH study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS)","volume":"11","author":"Gaudet","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"2019101710385722100_ref11","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jacl.2018.03.093","article-title":"Clinical and biochemical features of different molecular etiologies of familial chylomicronemia","volume":"12","author":"Hegele","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"2019101710385722100_ref12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2019101710385722100_ref13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"2019101710385722100_ref14","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1161\/ATVBAHA.108.175620","article-title":"Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients","volume":"28","author":"Stroes","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2019101710385722100_ref15","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/nbt1212-1153","article-title":"First gene therapy approved","volume":"30","author":"Moran","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"2019101710385722100_ref16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1089\/humc.2017.014","article-title":"Non-clinical study examining AAV8.TBG.hLDLR vector-associated toxicity in chow-fed wild-type and LDLR(+\/\u2212) rhesus macaques","volume":"28","author":"Greig","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"2019101710385722100_ref17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1089\/humc.2017.007","article-title":"Nonclinical pharmacology\/toxicology study of AAV8.TBG.mLDLR and AAV8.TBG.hLDLR in a mouse model of homozygous familial hypercholesterolemia","volume":"28","author":"Greig","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"2019101710385722100_ref18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat. Genet."},{"key":"2019101710385722100_ref19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"2019101710385722100_ref20","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2019101710385722100_ref21","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","article-title":"Permanent alteration of PCSK9 with in vivo CRISPR\u2013Cas9 genome editing","volume":"115","author":"Ding","year":"2014","journal-title":"Circ. Res."},{"key":"2019101710385722100_ref22","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1038\/s41467-018-04048-4","article-title":"RNA-guided transcriptional silencing in vivo with S. aureus CRISPR\u2013Cas9 repressors","volume":"9","author":"Thakore","year":"2018","journal-title":"Nat. Commun."},{"key":"2019101710385722100_ref23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"2019101710385722100_ref24","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1161\/ATVBAHA.116.307227","article-title":"CRISPR\u2013Cas9 targeting of PCSK9 in human hepatocytes in vivo-brief report","volume":"36","author":"Wang","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2019101710385722100_ref25","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.117.031335","article-title":"Reduced blood lipid levels with in vivo CRISPR\u2013Cas9 base editing of ANGPTL3","volume":"137","author":"Chadwick","year":"2018","journal-title":"Circulation"},{"key":"2019101710385722100_ref26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1042\/BJ20120146","article-title":"Lentiviral vectors: basic to translational","volume":"443","author":"Sakuma","year":"2012","journal-title":"Biochem. J."},{"key":"2019101710385722100_ref27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-43459-1","article-title":"Bile-duct proliferation as an unexpected side-effect after AAV2-LDLR gene transfer to rabbit liver","volume":"9","author":"Hyt\u00f6nen","year":"2019","journal-title":"Sci. Rep."},{"key":"2019101710385722100_ref28","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s12016-017-8611-x","article-title":"MicroRNAs: new therapeutic targets for familial hypercholesterolemia?","volume":"54","author":"Momtazi","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"2019101710385722100_ref29","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.bbrc.2018.08.205","article-title":"MicroRNA-98 regulates hepatic cholesterol metabolism via targeting sterol regulatory element-binding protein 2","volume":"504","author":"Geng","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2019101710385722100_ref30","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/CIRCULATIONAHA.117.029002","article-title":"Long noncoding RNA facilitated gene therapy reduces atherosclerosis in a murine model of familial hypercholesterolemia","volume":"136","author":"Tontonoz","year":"2017","journal-title":"Circulation"},{"key":"2019101710385722100_ref31","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz030","article-title":"Genome-wide identification of circulating-miRNA expression quantitative trait loci reveals the role of several miRNAs in the regulation of cardiometabolic phenotypes","author":"Nikpay","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"2019101710385722100_ref32","first-page":"57","article-title":"Identification of 12 novel loci that confer susceptibility to early-onset dyslipidemia","volume":"43","author":"Yamada","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"2019101710385722100_ref33","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.15252\/emmm.201505731","article-title":"VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption","volume":"7","author":"Nurmi","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"2019101710385722100_ref34","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/ATVBAHA.114.302528","article-title":"Lymphatic vessel insufficiency in hypercholesterolemic mice alters lipoprotein levels and promotes atherogenesis","volume":"34","author":"Vuorio","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2019101710385722100_ref35","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1161\/ATVBAHA.118.311549","article-title":"Deletion of lymphangiogenic and angiogenic growth factor VEGF-D leads to severe hyperlipidemia and delayed clearance of chylomicron remnants","volume":"38","author":"Tirronen","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2019101710385722100_ref36","doi-asserted-by":"crossref","first-page":"e010355","DOI":"10.1161\/JAHA.118.010355","article-title":"VEGF-C and mortality in patients with suspected or known coronary artery disease","volume":"7","author":"Wada","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"2019101710385722100_ref37","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jacc.2017.11.058","article-title":"Vascular endothelial growth factor D, pulmonary congestion, and incidence of heart failure","volume":"71","author":"Borne","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"2019101710385722100_ref38","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1136\/heartjnl-2018-313684","article-title":"Increased vascular endothelial growth factor D is associated with atrial fibrillation and ischaemic stroke","volume":"105","author":"Berntsson","year":"2019","journal-title":"Heart"}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/hmg\/advance-article-pdf\/doi\/10.1093\/hmg\/ddz132\/28854735\/ddz132.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/28\/R1\/R49\/30160322\/ddz132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/28\/R1\/R49\/30160322\/ddz132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T10:39:13Z","timestamp":1571308753000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hmg\/article\/28\/R1\/R49\/5520921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,22]]},"references-count":38,"journal-issue":{"issue":"R1","published-online":{"date-parts":[[2019,6,22]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddz132","relation":{},"ISSN":["0964-6906","1460-2083"],"issn-type":[{"value":"0964-6906","type":"print"},{"value":"1460-2083","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,6,22]]}}}